As a result of demographic change, the proportion of older oncology patients is rising sharply.
Compared to younger patients, cancer treatment is highly individualised due to more frequent and sometimes severe co-morbidities, increasing age-related infirmities and reduced physical fitness.
It is also important to consider the side effects of treatment, which can affect quality of life.
The standard treatment for head and neck cancer is either surgical removal of the tumour followed by radiotherapy, or organ-preserving radiotherapy in combination with chemotherapy.
The use of concomitant chemotherapy is particularly controversial because of the physical strain and side effects in older patients.
So far, there is only a limited amount of trial data on the best treatment.
An international study involving twelve university hospitals in Europe and the US has investigated the extent to which older head and neck cancer patients benefit from a combination of radiotherapy and chemotherapy on the one hand, or an alternative drug therapy with an antibody against a growth factor receptor (EGFR) on the other.
This clinical study shows that adding chemotherapy to radiotherapy is associated with a better chance of survival compared to radiotherapy alone.
This benefit was particularly pronounced in patients between 65 and 79 years of age and in those with good general health and few co-morbidities.
“In particular, fit older patients with minor co-morbidities should not be denied this effective therapy simply because of their advanced age,” explains study leader Professor Nils Nicolay: “In contrast, radiotherapy combined with taking the growth factor antibody showed no survival benefit compared to radiotherapy alone.”
To find out, the researchers analysed data from 1,044 older patients with head and neck squamous cell carcinoma of the oral cavity, pharynx or larynx who were treated with radiotherapy and, in some cases, in combination with a drug between 2005 and 2019.
Led by Leipzig University Hospital, a prospective international registry for older patients diagnosed with head and neck cancer is currently being set up.
More than 20 centres from Europe, the US and Australia have already expressed an interest in participating.
In addition to oncological data, the registry will record other parameters, including a comprehensive geriatric assessment, data on health-related quality of life, and the frequency of ‘decision regret’, i.e. the regret of the patient in choosing a particular therapy.
“In collaboration with other international research groups, additional modelling of the biological parameters will be carried out to better predict which older patients would benefit from combined radiotherapy and chemotherapy,” explains Dr Alexander Rühle, lead author and co-leader of the study.
“Tools will also be developed to facilitate joint therapy decisions based on individual patient data,” adds Professor Nicolay.
Professor Nils Nicolay and Dr Alexander Rühle started the study at the University of Freiburg Medical Center and completed it when they moved to Leipzig.
Nicolay has been Professor of Radiotherapy and Radiooncology at Leipzig University’s Faculty of Medicine since 1 September 2022.
The appointment also entails directing the Department of Radiooncology at Leipzig University Hospital.
Source: Leipzig University
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.